Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Specific Antiviral Drugs For COVID 19 Market Forecast: What Value Will The Market Reach By 2030?
The market size for specific antiviral drugs for covid 19 has witnessed rapid expansion in recent years. It is forecast to increase from $15.23 billion in 2025 to $17.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.1%. Several factors contributed to its growth in the past, including the swift spread of covid-19, the issuance of emergency use authorizations, the reliance on established antiviral drug classes, limitations in global production capacity, and elevated rates of hospitalization.
The market for specific antiviral drugs for covid 19 is poised for considerable expansion in the upcoming years. It is anticipated to achieve a valuation of $33.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 16.8%. This growth throughout the forecast period can be attributed to several factors, including the advancement of next-generation antiviral drugs, an increase in public-private partnerships, the rising adoption of preventive treatments, the expansion of combination therapies, and the integration of personalized medicine approaches. Key trends expected during this period involve a surge in investment for covid-19 antiviral drug development, the increasing use of oral antiviral tablets, the growth of monoclonal antibody therapies, the broadening of hospital and retail distribution channels, and a focused effort on targeted treatment for hospitalized and high-risk patients.
Get A Free Sample Report With In-Depth Market Insights:
Specific Antiviral Drugs For COVID 19 Market Growth Momentum: What Factors Are Shaping Demand?
The escalating count of COVID-19 infections is anticipated to stimulate the future expansion of the specific antiviral drugs for the COVID-19 market. COVID-19 cases pertain to individuals who have tested positive for the SARS-CoV-2 virus, which is responsible for COVID-19. The increase in COVID-19 cases is attributable to the emergence of new variants that exhibit easier transmission and a partial ability to evade immunity from prior vaccinations or infections. Specific antiviral drugs for COVID-19 are beneficial in mitigating the illness’s severity and duration, thus enhancing patient outcomes and reducing the overall impact of COVID-19 cases. For example, in May 2025, the World Health Organization, a global public health agency based in Switzerland, reported that the Eastern Mediterranean region’s test positivity rate surged from 4% to 17% in early 2025, surpassing the figures for the equivalent period in 2024. This rising number of COVID-19 cases therefore propels the growth of the specific antiviral drugs for the COVID-19 market.
Specific Antiviral Drugs For COVID 19 Market Breakdown By Product Type And Application
The specific antiviral drugs for covid 19 market covered in this report is segmented –
1) By Type: Tablet, Injection
2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment
3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies
4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets
2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections
Specific Antiviral Drugs For COVID 19 Market Trends Redefining Industry Growth
Key players within the specific antiviral drugs for the COVID-19 market are concentrating their efforts on creating groundbreaking treatments, like oral antiviral therapies, aimed at improving both the availability and efficacy of care. Oral antiviral therapies are medications administered orally to prevent the replication of viruses such as COVID-19, providing a practical and potent treatment solution. As an illustration, in March 2024, Shionogi And Co., a pharmaceutical company based in Japan, released Xocova and received full standard endorsement from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its antiviral drug ensitrelvir. Moreover, it also delivers post-exposure prophylaxis by considerably decreasing the chance of symptomatic COVID-19 developing in individuals who have been exposed, and it shortens the duration of symptoms while demonstrating a positive safety profile.
Specific Antiviral Drugs For COVID 19 Market Company Landscape And Competitive Strategy
Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.
View The Full Specific Antiviral Drugs For COVID 19 Market Report:
Specific Antiviral Drugs For COVID 19 Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model